In August 2025, India’s IPO market continues to attract investors seeking opportunities in the pharmaceutical sector. Among the notable upcoming listings is Amanta Healthcare Limited, a company with a strong presence in the development, manufacturing, and marketing of sterile liquid formulations and medical devices.
Against this backdrop, Amanta Healthcare Limited IPO is set to open on September 1, 2025. Here is a detailed insight into the company, its IPO, and industry outlook.
About Amanta Healthcare Ltd.
Incorporated in December 1994, Amanta Healthcare Limited specializes in the production of parenteral products packaged in plastic containers using Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies. The company also manufactures a range of medical devices.
Its portfolio includes:
- Fluid therapy formulations: IV fluids, diluents, ophthalmic solutions, respiratory care products
- Irrigation solutions, first-aid products, eye lubricants
Amanta Healthcare markets its products through three business units:
- National sales
- International sales
- Product partnering with Indian and foreign pharmaceutical companies
The company sells products in Africa, Latin America, the UK, and beyond, with registrations in 19 countries. As of March 31, 2025, Amanta Healthcare has a team of 1,718 employees across formulation, development, and quality laboratory functions.
Competitive Strengths
- Well-established manufacturer with a diverse product portfolio
- Large domestic and international manufacturing capabilities
- Extensive domestic and international marketing network
- Experienced management supported by a skilled workforce
Amanta Healthcare IPO Details
| Particulars | Details |
| IPO Date | September 1, 2025 – September 3, 2025 |
| Listing Date (Tentative) | September 9, 2025 |
| Face Value | ₹10 per share |
| Issue Price Band | ₹120 – ₹126 per share |
| Lot Size | 119 Shares |
| Sale Type | Fresh Capital |
| Total Issue Size | 1,00,00,000 shares (up to ₹126.00 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Shareholding Pre-Issue | 2,88,29,351 shares |
| Shareholding Post-Issue | 3,88,29,351 shares |
Amanta Healthcare IPO Timeline (Tentative Schedule)
| Event | Date |
| IPO Open Date | Mon, Sep 1, 2025 |
| IPO Close Date | Wed, Sep 3, 2025 |
| Tentative Allotment Date | Thu, Sep 4, 2025 |
| Initiation of Refunds | Mon, Sep 8, 2025 |
| Credit of Shares to Demat | Mon, Sep 8, 2025 |
| Tentative Listing Date | Tue, Sep 9, 2025 |
| Cut-off time for UPI mandate confirmation | 5 PM on Sep 3, 2025 |
Amanta Healthcare IPO Lot Size
| Application | Lots | Shares | Amount |
| Retail (Min) | 1 | 119 | ₹14,994 |
| Retail (Max) | 13 | 1,547 | ₹1,94,922 |
| S-HNI (Min) | 14 | 1,666 | ₹2,09,916 |
| S-HNI (Max) | 66 | 7,854 | ₹9,89,604 |
| B-HNI (Min) | 67 | 7,973 | ₹10,04,598 |
Amanta Healthcare IPO Promoter Holding
| Promoter | Shareholding Pre-Issue | Shareholding Post-Issue |
| Bhavesh Patel, Vishal Patel, Jayshreeben Patel, Jitendra Kumar Patel, Milcent Appliances Pvt. Ltd. | 85.60% | 63.56% |
Objects of the Issue
| S.No | Objects of the Issue | Expected Amount (₹ Crores) |
| 1 | Funding capital expenditure for civil construction and equipment for new SteriPort manufacturing line at Hariyala, Kheda, Gujarat | 70.00 |
| 2 | Funding capital expenditure for civil construction and equipment for new SVP manufacturing line at Hariyala, Kheda, Gujarat | 30.13 |
| 3 | General corporate purposes | – |
Amanta Healthcare Ltd. Financials
Restated Financial Information (₹ Crores)
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 381.76 | 352.12 | 374.06 |
| Total Income | 276.09 | 281.61 | 262.70 |
| Profit After Tax | 10.50 | 3.63 | -2.11 |
| EBITDA | 61.05 | 58.76 | 56.31 |
| Net Worth | 96.39 | 66.29 | 62.88 |
| Reserves & Surplus | 67.56 | 39.46 | 36.05 |
| Total Borrowing | 195.00 | 205.23 | 215.66 |
Key Performance Indicators (KPI)
The market capitalisation of Amanta Healthcare IPO is ₹489.25 Cr.
| KPI | Values |
| ROE | 12.42% |
| ROCE | 13.72% |
| Debt/Equity | 2.02 |
| RoNW | 10.89% |
| PAT Margin | 3.86% |
| EBITDA Margin | 22.11% |
| Price to Book Value | 3.77 |
| EPS (Pre IPO) (Rs) | 3.64 |
| EPS (Post IPO) (Rs) | 2.70 |
| P/E (Pre IPO) (x) | 34.59 |
| P/E (Post IPO) (x) | 46.59 |
Amanta Healthcare IPO Reservation
| Investor Category | Shares Offered |
| QIB | Not more than 50.00% of Net Issue |
| Retail | Not less than 35.00% of Net Issue |
| NII | Not less than 15.00% of Net Issue |
Amanta Healthcare IPO: Industry Outlook
- Global pharmaceutical market continues to expand with growing demand for sterile formulations.
- Increasing demand for intravenous fluids, ophthalmic, and respiratory care products in emerging markets.
- India’s pharmaceutical exports and compliance with international regulations enhances global competitiveness.
- Growing focus on healthcare infrastructure in Africa, Latin America, and the UK provides ample growth opportunities.
Peer Comparison
Amanta Healthcare Ltd. operates in a competitive pharmaceutical space alongside peers like Denis Chem Lab Limited, which also focuses on sterile liquid products and medical devices.
Conclusion
Amanta Healthcare Limited presents an attractive investment opportunity in the pharmaceutical and medical device sector, backed by a diverse product portfolio, large domestic and international presence, and robust financials. However, investors should consider risks, including regulatory challenges, operational dependencies, and market competition, before making investment decisions.
If you are exploring more investment opportunities, check out our dedicated page on upcoming IPO listings to stay updated on the latest market offerings.
